
    
      The design is a double-blind, placebo-controlled, crossover study conducted at a single site.
      The primary variable is a change from baseline to Week 16 in plasma glucose area under the
      curve during a three-hour oral glucose tolerance test. Secondary variables include changes in
      fasting levels of glucose and insulin, glucose tolerance, hemoglobinA1c, hepatic enzymes,
      adipocytokines, blood lipid profile, and body composition. Supporting endpoints include
      dietary intake, physical activity, fatty acids, and vital signs.
    
  